The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

The most commonly reported ocular features of infection include: linearly arranged or scattered chorioretinal lesions, anterior uveitis, retinal vasculitis, optic neuritis and vitritis.

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory ...

The ASRS noted that since approval on 7th October last year there have been 14 cases of vasculitis – inflammation of the blood vessels – with 11 reported to be occlusive retinal vasculitis ...

retinal vasculitis and vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapse, sight-threatening eye disease or irreversible organ ...

Specifically, Syfovre has been linked to several cases of retinal vasculitis, some of which were severe enough to block blood flow in the retina, raising the risk of sight loss. Apellis has ...

Retinal artery blockage, endophthalmitis or vasculitis, were not recorded as causes of intraocular inflammation.Defined as baseline central subfield thickness ? 400 microns, UBX1325 was ...